Forge Biologics

Executive Summary

Forge Biologics is a rapidly growing contract development and manufacturing organization (CDMO) exclusively focused on adeno-associated virus (AAV) vector production for gene therapies. Founded in 2020 and headquartered in Columbus, Ohio, the company operates a large-scale current Good Manufacturing Practice (cGMP) facility capable of supporting programs from process development to commercial manufacturing. By offering end-to-end services, Forge aims to accelerate gene therapy development and improve patient access. The company's specialized focus on AAV vectors positions it well in a high-demand segment of the biopharmaceutical market, as gene therapies continue to gain regulatory approvals and expand into new indications. With a modern facility and a dedicated team, Forge has the potential to capture significant market share in the outsourced AAV manufacturing space. Despite being a relatively new entrant, Forge Biologics faces intense competition from established CDMOs and larger contract manufacturers. Its success hinges on building a robust client pipeline, securing partnerships with gene therapy developers, and demonstrating reliable manufacturing at scale. The company's private status limits public visibility, but its strategic location and focused capabilities are attractive to sponsors seeking specialized AAV expertise. Over the near term, Forge's growth will likely be driven by new customer wins, capacity expansions, and potential collaborations that leverage its proprietary manufacturing platform.

Upcoming Catalysts (preview)

• Q3 2026Announcement of major partnership with a top-20 pharma for AAV gene therapy manufacturing40% success
• Q4 2026Expansion of manufacturing capacity or new facility to meet growing demand50% success
• Q2 2026Completion of a successful regulatory inspection (e.g., FDA) for a client's gene therapy product60% success